Epigenetics and Chromatin Biology Group, Gupta Laboratory, Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, MH, 410210, India.
Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, MH, 400085, India.
Epigenetics Chromatin. 2020 Aug 3;13(1):31. doi: 10.1186/s13072-020-00354-8.
Epigenetics research is progressing in basic, pre-clinical and clinical studies using various model systems. Hence, updating the knowledge and integration of biological data emerging from in silico, in vitro and in vivo studies for different epigenetic factors is essential. Moreover, new drugs are being discovered which target various epigenetic proteins, tested in pre-clinical studies, clinical trials and approved by the FDA. It brings distinct challenges as well as opportunities to update the existing HIstome database for implementing and applying enormous data for biomedical research.
HISTome2 focuses on the sub-classification of histone proteins as variants and isoforms, post-translational modifications (PTMs) and modifying enzymes for humans (Homo sapiens), rat (Rattus norvegicus) and mouse (Mus musculus) on one interface for integrative analysis. It contains 232, 267 and 350 entries for histone proteins (non-canonical/variants and canonical/isoforms), PTMs and modifying enzymes respectively for human, rat, and mouse. Around 200 EpiDrugs for various classes of epigenetic modifiers, their clinical trial status, and pharmacological relevance have been provided in HISTome2. The additional features like 'Clustal omega' for multiple sequence alignment, link to 'FireBrowse' to visualize TCGA expression data and 'TargetScanHuman' for miRNA targets have been included in the database.
The information for multiple organisms and EpiDrugs on a common platform will accelerate the understanding and future development of drugs. Overall, HISTome2 has significantly increased the extent and diversity of its content which will serve as a 'knowledge Infobase' for biologists, pharmacologists, and clinicians. HISTome2: The HISTone Infobase is freely available on http://www.actrec.gov.in/histome2/ .
表观遗传学研究在基础、临床前和临床研究中使用各种模型系统取得了进展。因此,更新知识并整合来自不同表观遗传因子的计算机模拟、体外和体内研究中出现的生物数据是至关重要的。此外,正在发现针对各种表观遗传蛋白的新药,这些药物已在临床前研究中进行了测试,并已获得 FDA 的批准。这为更新现有的 HIstome 数据库以实施和应用大量生物医学研究数据带来了独特的挑战和机遇。
HISTome2 专注于人类(Homo sapiens)、大鼠(Rattus norvegicus)和小鼠(Mus musculus)的组蛋白蛋白作为变体和同工型、翻译后修饰(PTMs)和修饰酶的亚分类,在一个界面上进行综合分析。它包含了 232、267 和 350 个条目,分别用于人类、大鼠和小鼠的组蛋白蛋白(非规范/变体和规范/同工型)、PTMs 和修饰酶。在 HISTome2 中提供了 200 多种不同类别的表观遗传修饰剂的 EpiDrugs,及其临床试验状态和药理学相关性。该数据库还包含了其他功能,如用于多序列比对的'Clustal omega'、用于可视化 TCGA 表达数据的 'FireBrowse'链接和用于 miRNA 靶标的 'TargetScanHuman'。
在一个共同的平台上提供多个生物体和 EpiDrugs 的信息将加速对药物的理解和未来发展。总的来说,HISTome2 大大增加了其内容的广度和多样性,将成为生物学家、药理学家和临床医生的“知识信息库”。HISTome2:HISTone Infobase 可在 http://www.actrec.gov.in/histome2/ 上免费获取。